Timothy C. Thompson

Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Supplementary Table S13. Quantification of each protein-specific band normalized to vinculin (macrophage cells (RAW264.7) mono- or cocultured with RM-1-BM EV or SPOPmut models under treatment with OLA, Fig. 5E).

Year:

2025

Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR

Year:

2025

Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle

Year:

2025

Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.

Year:

2025

Supplementary Table S2. Listing of protein features differentially expressed in Dox-inducible SPOPmut (F102C and F133V) C4-2b prostate cancer cells compared to C4-2b vector control shown in Fig. 2A upper panel

Year:

2025

Supplementary Fig. S21. Double immunofluorescence staining analysis of cleaved caspase 3 and PARP1 in C4-2b-empty vector and C4-2b-SPOPF133V xenograft tumors treated with talazoparib (TALA) or control vehicle

Year:

2024

Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR

Year:

2024

Supplementary Fig. S19. Heatmaps of common differentially expressed genes in co-cultured and mono-cultured prostate cancer model tumor cells demonstrating significant (FDR

Year:

2024

Purpose: Speckle-type POZ protein (SPOP) is important in DNA damage response (DDR) and maintenance of genomic stability. Somatic heterozygous missense mutations in the SPOP1 substrate-binding cleft are found in up to 15% of prostate cancers. While mutations in SPOP predict for benefit from androgen receptor signaling inhibition (ARSi) therapy, outcomes for patients with SPOP-mutant (SPOPmut) prostate cancer are heterogeneous and targeted treatments for SPOPmut castrate-resistant prostate cancer (CRPC) are lacking. Experimental Design: Using in silico genomic and transcriptomic tumor data, proteomics analysis and genetically modified cell line models we demonstrate mechanistic links between SPOP mutations, STING signaling alterations and PARP inhibitor vulnerabilities. Results: We demonstrate that SPOP mutations are associated with upregulation of a 29-gene non-canonical (NC) STING1 (NC-STING) signature in a subset of SPOPmut, treatment-refractory CRPC patients. We show in preclinical CRPC models that SPOP targets and destabilizes STING protein, and prostate cancer ̶ associated SPOP mutations result in upregulated NC-STING-NF-κB signaling and macrophage- and tumor microenvironment (TME)-facilitated reprogramming, leading to tumor cell growth. Importantly, we provide in vitro and in vivo mechanism-based evidence that PARP inhibitor (PARPi) treatment results in a shift from immunosuppressive NC-STING-NF-κB signaling to anti-tumor, canonical cGAS-STING-IFN-β signaling in SPOPmut CRPC and results in enhanced tumor growth inhibition. Conclusions: We provide evidence that SPOP is critical in regulating immunosuppressive versus anti-tumor activity downstream of DNA damage-induced STING activation in prostate cancer. PARPi treatment of SPOPmut CRPC alters this NC-STING signaling toward canonical, anti-tumor cGAS-STING-IFN-β signaling, highlighting a novel biomarker-informed treatment strategy for prostate cancer.

Year:

2024

Supplementary Table S3. Complete listing of antibodies used for immunoblotting (IB) and immunostaining analysis (Fig. 6C, 6D and Extended Data Fig. 5, 6). Vendor and catalog numbers are included in the list.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (6)

Johannes Fahrmann

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Massimo Loda

Chair

Weill Cornell Medical College

UNITED STATES
View details

Jody Vykoukal

Group Leader

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paul Corn

Chair

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details